BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SciLifeLab - ECPv6.17.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SciLifeLab
X-ORIGINAL-URL:https://www.scilifelab.se
X-WR-CALDESC:Events for SciLifeLab
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20261014T084500
DTEND;TZID=Europe/Stockholm:20261014T170000
DTSTAMP:20260824T073159Z
CREATED:20251219T121224Z
LAST-MODIFIED:20260824T073159Z
UID:192929-1791967500-1791997200@www.scilifelab.se
SUMMARY:SciLifeLab Science Summit
DESCRIPTION:The Annual Conference SciLifeLab Science Summit is a one-day symposium with a new topic each year. The 2026 topic is: \n\n\n\nCancer Research: Translating Life Science Discoveries to Clinical Breakthroughs\n\n\n\nFor more than a century\, Swedish cancer research has shaped the international scientific landscape\, driven by strong academic environments and a deep societal commitment to transforming discoveries into better treatments. From breakthroughs in cancer genomics and tumor biology to advances in immunology and angiogenesis\, researchers in Sweden continue to push the boundaries of life science and medicine. \n\n\n\nThe SciLifeLab Science Summit brings this legacy into the future by uniting world-leading cancer researchers with cutting-edge technologies across genomics\, proteomics\, imaging\, data science\, and beyond. The summit creates an inspiring forum where scientific excellence meets societal relevance—fostering collaboration\, showcasing groundbreaking research\, and highlighting how cancer research continues to reveal fundamental mechanisms of life while driving innovation with real-world impact. \n\n\n\nThe conference is free of charge. Fika\, lunch and Meet-the-speaker-mingle will be included (only) if you register before deadline on September 21. \n\n\n\nJoin us for a full day of inspiring Science! \n\n\n\nScientific Committee\n\n\n\n\nAnna Dimberg\, Uppsala University (chair)\n\n\n\nPanagiotis Baliakas\, Uppsala University\n\n\n\nGunilla Enblad\, Uppsala University\n\n\n\nCamilla Engblom\, Karolinska Institutet (KI)\n\n\n\nMaréne Landström\, Umeå University\n\n\n\nAris Moustakas\, Uppsala University\n\n\n\nJessica Nordlund\, Uppsala University\n\n\n\nKristian Pietras\, Lund University\n\n\n\nCarina Strell\, Uppsala University and University of Bergen\n\n\n\n\nProject leader: Erika Erkstam\, Operations Office\, SciLifeLab \n\n\n\nRegistration\n\n\n\nDeadline (for registration and posters): September 21 \n\n\n\nRegister here\n\n\n\nQuestions? If you have any inquiries regarding the event or your registration\, please contact events@scilifelab.se \n\n\n\nFor late registrations (after September 21)\, we cannot guarantee lunch\, coffee\, nor can we accommodate any allergies or dietary requirements. These will be subject to availability. We appreciate your understanding. \n\n\n\n\n\n\n\nSpeakers\n\n\n\n\nAngelica Loskog\, Uppsala University\n\n\n\nAnna Martner\, University of Gothenburg. Sahlgrenska Center for Cancer Research\n\n\n\nAri Molofsky\, University of California\, San Francisco\, US.\n\n\n\nBernd Bodenmiller\, University of Zurich and ETH Zurich\, Switzerland\n\n\n\nGabriele Bergers\, VIB-KU Leuven Center for Cancer Biology\, Belgium\n\n\n\nGunilla Edblad\, Uppsala University and Uppsala University Hospital\n\n\n\nGöran B. Jönsson\, Lund University\n\n\n\nJosé Ignacio Martín-Subero\, Institució Catalana de Recerca i Estudis Avançats (ICREA)\, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)\, Spain\n\n\n\nThoas Fioretos\, Lund University\n\n\n\n\nProf. Angelica Loskog\nUppsala University\, Sweden. \n\n\n\nTitle: Evoking Tumor Immunity in Immune-Resistant Cancers  \n\n\n\nAbstract:  \n\n\n\nGrauers Wiktorin H1\, Lövgren T1\, Wenthe J1\, Ritter A1\, Calandegary A1\, Ekström Ryden V\,1\,2 Hahn A1\,2\, Hamid O3\, Gustafsson Liljefors M4\, Musher BL5\, Brenner MK5\, Ullenhag G1\,2\, Loskog A1\,6. \n\n\n\n1Uppsala University\, Uppsala\, Sweden \n\n\n\n2Uppsala University Hospital\, Uppsala\, Sweden \n\n\n\n3The Angeles Clinic and Research Institute\, A Cedars Sinai Affiliate\, Los Angeles\, CA\, USA \n\n\n\n4Karolinska Hospital\, Huddinge\, Sweden \n\n\n\n4Baylor College of Medicine\, Houston\, TX\, USA \n\n\n\n6Lokon Pharma AB\, Uppsala\, Sweden \n\n\n\nImmunotherapy for cancer is a cornerstone of cancer treatment but despite the initial success\, many patients are either primary resistant or develop resistance during treatment. By engineering the tumor microenvironment using and oncolytic adenoviral gene vector encoding TMZ-CD40L and 4-1BBL (LOAd703)\, we aim to rewire the immunosuppressive state in the patients to drive anti-tumor immune responses allowing for continued immune checkpoint inhibitor (ICI) treatment of refractor patients and/or ICI treatment of indications previously not responding to ICI. LOAd703 plus ICI have been tested in melanoma patients (n=24) refractory to one or several lines of prior ICI\, and in pancreatic cancer patients (LOAd703 +standard chemotherapy\, n=21; LOAd703 + ICI + standard chemotherapy\, n=24) who are commonly not responding to ICI. In these Phase I/II clinical trials blood and biopsies were analyzed for the initiation of immune responses locally in the tumor microenvironment as well as systemically in blood. \n\n\n\nThe treatment was well tolerated with common adverse events related to chemotherapy (pancreatic cancer) or ICI (melanoma and pancreatic cancer). LOAd703 attributed adverse events included fever\, chills\, and cytokine release syndrome\, mostly grade 1 or 2. Both in melanoma and pancreatic cancer\, LOAd703 promoted a typical Th1 type of immune response post treatment initiation which was noted both in the tumor and in blood. Similarly\, tumor responses were noted in both indications as evaluated with Olink proteomics\, NanoString Technology\, and flow cytometry. In conclusion\, LOAd703 can be used together with chemotherapy and/or ICI treatment to rewire the immunosuppressive state in patients towards Th1 immunity and subsequently controlling tumor growth in patients. \n\n\n\n \n\n\n\n\nProf. Anna Martner\nUniversity of Gothenburg\, Sweden.  \n\n\n\nTitle: NOX2-derived ROS as drivers of metastatic progression \n\n\n\nBiosketch: Anna Martner is a group leader at the Sahlgrenska Center for Cancer Research\, University of Gothenburg. Her research focuses on myeloid cell-mediated immunosuppression\, NOX2-derived ROS\, tumor cell plasticity\, and metastasis. She trained with Professors Kristoffer Hellstrand and Dmitry Gabrilovich and spent a 2019 sabbatical in Professor Robert Weinberg’s laboratory at MIT studying EMT. \n\n\n\nAbstract: The efficacy of cancer immunotherapy depends on the balance between anti-tumor effector cells\, including natural killer (NK) cells and T cells\, and mechanisms of tumor-associated immunosuppression. Inflammatory myeloid cells\, including myeloid-derived suppressor cells (MDSCs)\, contribute to immune evasion through several mechanisms\, among them the production of reactive oxygen species (ROS) by NOX2. \n\n\n\nOur group investigates the role of NOX2-derived ROS in cancer-associated immunosuppression and metastasis\, and the potential of targeting this pathway therapeutically. We have shown that genetic or pharmacological inhibition of NOX2 promotes NK cell-mediated clearance of metastatic tumor cells and enhances the efficacy of immune checkpoint blockade (Aydin et al.\, Cancer Immunol Res\, 2017; Grauers Wiktorin et al.\, Cancer Immunol Immunother\, 2019). We also found that surgical stress aggravates NOX2-dependent immunosuppression and metastatic progression\, effects that can be counteracted by NOX2 inhibition (Grauers Wiktorin et al.\, Cancer Res Commun\, 2024). \n\n\n\nMore recently\, we found that myeloid cell-derived NOX2-generated ROS can act directly on tumor cells. These ROS induce epigenetic changes that activate epithelial-to-mesenchymal transition (EMT) programs and promote metastasis (Kaya et al.\, PNAS\, 2026). Thus\, NOX2-derived ROS may promote metastatic progression both by suppressing anti-tumor immunity and by enhancing tumor cell plasticity. \n\n\n\nHistamine dihydrochloride (HDC)\, which inhibits NOX2-dependent ROS formation\, is approved in the EU for relapse prevention in acute myeloid leukemia. In an ongoing clinical trial at the Sahlgrenska University Hospital\, we are investigating HDC in combination with IL-2 in patients undergoing surgery for pancreatic cancer\, with the aim of reducing perioperative immunosuppression and metastatic risk. \n\n\n\n\nProf. Ari Molofsky\nUniversity of California\, San Francisco \n\n\n\nTitle: Fibroblast – Immune niches in health and disease. \n\n\n\nBiosketch: Ari Molofsky received a BS with highest honors from the University of Texas at Austin and an MD/PhD with research distinction from the University of Michigan in Ann Arbor. Dr. Molofsky completed residency and fellowship in Clinical Pathology/Hematopathology and now leads a tissue immunology-focused research group in the Department of Laboratory Medicine at UCSF. Dr. Molofsky’s research goals are to understand the regulation and function of tissue-resident immune cells to define novel pathways that can be targeted across diverse human diseases. These tissue-resident immune cells are early organizers of tissue remodeling and first responders during tissue damage and infection\, positioning them as key mediators of tissue health and disease. The Molofsky lab has defined a stromal-immune niche surrounding larger vessels and other border structures in multiple tissues\, including the lungs and brain. They are using 3D quantitative microscopy\, single-cell and spatial transcriptomics\, and cytokine reporters/manipulators to dissect these critical immune-microenvironment interactions\, with a particular focus on bidirectional interactions with fibroblasts. Dr. Molofsky has published papers spanning microbial pathogenesis\, tissue-resident immunity\, and local immune niches. Dr. Molofsky is actively involved in trainee education and teaching and leads the UCSF medical school immunology course. Dr. Molofsky routinely serves as an ad hoc reviewer for multiple journals and is a standing member of the NIH Innate Immunity study section. \n\n\n\nAbstract: \n\n\n\n\nProf. Bernd Bodenmiller\nUniversity of Zurich and ETH Zurich\, Switzerland \n\n\n\nTitle:  \n\n\n\nBiosketch: Bernd Bodenmiller is a quantitative biologist who develops novel experimental and computational approaches for the quantitative analysis of tumor ecosystems to improve our understanding of the mechanisms of tumor development for the benefit of patients. He is the founding director of the Department of Quantitative Biomedicine (DQBM) at the University of Zurich\, which fosters research and education at the interface of biomedical research\, biotechnology\, and computational biology to guide development of next-generation precision medicine. Prof. Bodenmiller obtained his PhD in the group of Ruedi Aebersold at ETH Zürich. For his postdoctoral training\, he joined the laboratory of Garry P. Nolan at Stanford University. In 2012\, he became a group leader and in 2013 an SNF/ERC assistant professor at the University of Zürich. In 2019\, he was tenured and became the founding director of the DQBM. In October 2020 Prof. Bodenmiller has been appointed as Dual Professor for Quantitative Biomedicine at the UZH and at ETH Zurich. His group pioneered the development of imaging mass cytometry\, an approach that enables simultaneously imaging of over 40 proteins and transcripts in tumor tissues (Nat. Methods\, 2014; Cell Systems\, 2017; Nature 2020) and the histoCAT software toolbox (Nat. Methods\, 2017). His groups applies these methods to unravel how cells in the tumor ecosystem drive cancer development to identify mechanisms that might be exploited for therapeutic targeting (Nat. Biotechnology\, 2017\, Cell\, 2017; Cell\, 2019). \n\n\n\n\nProf. Göran Jönsson\nLund University \n\n\n\nTitle: Exploring the role of the anti-tumor immune response in tumor initiation and therapy response in melanoma \n\n\n\nBiosketch: Göran Jönsson is a professor in molecular oncology at Lund University. His research has for many years been based on strong collaboration between basic- and clinician scientists in truly translational projects. Considering this and his background in state-of-the art genomic technologies and applying that on human melanoma tissue puts him in a perfect position to conduct research that will generate groundbreaking findings. This is further substantiated by the group’s publication in Nature (2020). Göran is a faculty member of ESMO (European Society of Medical Oncology) and have an extensive international network. He is frequently invited to large international meetings and acts as a reviewer to several funding agencies and high-impact journals such as Nature. Göran has also been the recipient of Young and Senior Investigator Awards from the Swedish Cancer Society and more recently was awarded with the Göran Gustafsson prize in medicine 2022 from the Royal Swedish Academy of Sciences and Cancer Researcher of the year (2023) from the Swedish Cancer Society. \n\n\n\nAbstract: \n\n\n\n \n\n\n\n\nProf. José Ignacio Martín-Subero\nIDIBAPS\, Spain \n\n\n\nTitle: \n\n\n\nBiosketch: In 2001\, I obtained my PhD in Biochemistry from the University of Navarra on genetics of lymphoid neoplasms under the supervision of Prof. Maria J Calasanz and co-supervision of Prof. Reiner Siebert from the Christian-Albrechts University of Kiel. After that\, I continued my studies on lymphoma genetics as postdoctoral fellow with Prof. Siebert. In 2005\, I became interested in the field of epigenomics and in 2009 I came back to Spain. After a short stay at the IDIBELL\, I went to the UB/IDIBAPS to start my career as independent researcher embedded in the group of Prof. Elias Campo. In 2016\, I was appointed Junior Leader of the Biomedical Epigenomics group at the IDIBAPS and from November 2018 I am ICREA Research Professor at the IDIBAPS. I also have an appointment as associate professor at the UB. Our group is interested in the role of epigenetics in the origin\, evolution and clinical manifestations of lymphoid tumors. \n\n\n\n\nProf. Thoas Fioretos\nLund University \n\n\n\nTitle: From Genomic Discoveries to Better Diagnostics and Therapies in Acute Leukemia \n\n\n\nAbstract: \n\n\n\n \n\n\n\n \n\n\n\n\nProgram\n\n\n\nMore information will follow. \n\n\n\n08:45Registration and coffee\, poster hanging.Please leave large bags and outerwear in the staffed Cloakroom.09:00Doors open. Be seated at 09:1509:15Welcome by SciLifeLab Director Jan Ellenberg09:35Session 1: Immune Niches in CancerModerator: Anna DimbergGabriele Bergers\, VIB-KU Leuven Center for Cancer Biology\, BelgiumGöran Jönsson\, Lund University\, SwedenFlash Talks10:45Coffee and Poster session (odd numbers)11:25Session 2: Tumor Microenvironment and Clinical TranslationModerator: Carina StrellAri Molofsky\, University of California\, San Francisco (UCSF)\, USAngelica Loskog\, Uppsala University\, SwedenGunilla Enblad\, Uppsala University and Uppsala University Hospital\, Sweden12:45Lunch13:45Session 3: Precision OncologyModerator: Jessica Nordlund & Panagiotis BaliakasJosé Ignacio Martín-Subero\, ICREA-IDIBAPS\, SpainThoas Fioretos\, Lund University\, Sweden14:45Roundtable discussion: What is needed to translate Swedish cancer discoveries into clinical implementation?Moderator: Anna DimbergPanelists: Gunilla Enblad\, Thoas Fioretos\, Maréne Landström\, Angelica Loskog\, Kristian Sandberg.Flash Talks15:15Coffee and Poster session (even numbers)15:55Session 4: Tumor Ecosystems and Spatial BiologyModerator: Aristidis MoustakasBernd Bodenmiller\, University of Zurich and ETH Zurich\, SwitzerlandAnna Martner\, Sahlgrenska Center for Cancer Research\, Sweden16:50Best Poster Award and Closing word; Jan Ellenberg\, Director\, SciLifeLab17:00Meet-the-speaker and network mingle with snacks and beverages18:15End of SciLifeLab Science Summit\n\n\n\n \n\n\n\nPoster session\n\n\n\nEveryone\, especially junior (PhD and postdoc) researchers are encouraged to participate with poster presentations and have the opportunity to win the Best Poster Award. \n\n\n\nDetails about the Poster session\nPoster Presentation Guidelines \n\n\n\nPoster Format \n\n\n\nThe poster boards are 103 cm wide and 143 cm high. \n\n\n\nMount your poster \n\n\n\nThe venue will be open from 8:45 AM. Please proceed to the 6th floor and hang your poster at your designated number. A numbered poster list will be provided closer to the event date. \n\n\n\nPoster sessions \n\n\n\nPoster Session I: During the morning coffee break\, presenters of posters with odd numbers (1\, 3\, 5\, 7…) should be present by their posters. \n\n\n\nPoster Session II: During the afternoon break\, presenters of posters with even numbers (2\, 4\, 6\, 8…) should be present by their posters. \n\n\n\nBest Poster Award \n\n\n\nAll poster presenters should attend the Best Poster Award ceremony at the end of the conference\, where the Best Poster Award will be announced. The Poster Jury will read the abstracts and evaluate the posters throughout the day based on (a) Quality of Science (b) Design (c) Capacity to explain the work. The Poster Jury will select the 2026 Science Summit Best Poster and award the winner a 5\,000 SEK Travel Grant (conditions apply). \n\n\n\nFlash Talks (5-min research pitch) selected from Abstracts. \n\n\n\nThe abstracts will be published on the event website and used to select Flash Talks (5-min research pitch).  \n\n\n\nDismount of posters \n\n\n\nPlease remove your poster immediately after the closing session at 5:00 PM. Poster screens will be collected at 5:30 PM\, and any remaining posters will be discarded. \n\n\n\n\nBest Poster Award\n\n\n\nThe Poster jury\, consisting of SciLifeLab Fellows\, will nominate the Science Summit 2026 Best Poster and award the winner a 5 000 SEK Travel Grant. \n\n\n\nSpread the word – download the flyer\n\n\n\nDigital sign_SS26_qrDownload\n\n\n\n\n\n\n\nPractical information\n\n\n\nTravel to Uppsala\n\n\n\nThe Venue\, Uppsala Konsert & Kongress (UKK) is next to the Train station. MAP here! Travel centres\, bus stops\, parking and hotels are all located within walking distance from Uppsala Konsert & Kongress. Several train and bus lines connect Uppsala to the rest of the country and the region\, and Arlanda Airport is only 18 minutes by train\, Stockholm Central station is approx. 30 minutes by train. \n\n\n\nUppland public transport (UL) timetables and information: www.ul.seStockholm public transport (SL) timetables and information: www.sl.se SJ timestables and information: www.sj.se \n\n\n\nGood to know\, travelling to Uppsala. \n\n\n\nParking\n\n\n\nThe nearest parking garage is Centralgaraget. There is also parking available in Kvarnens parking garage\, Svava\, S:t Per Gallerians garage\, Österplan\, and several other locations in central Uppsala. For more information about parking in the area\, please visit Uppsala Parkering. \n\n\n\nHotels in Uppsala\n\n\n\nFind suggestions for accommodation in Uppsala here \n\n\n\n\nImproved event experience: Introducing the Lyyti Event app \n\n\n\nThis event uses Lyyti for registration. Lyyti has launched the Lyyti Event app\, where you can find your Lyyti registration\, confirmation\, and ticket. You can also edit your information until the registration deadline. \n\n\n\nTo get started\, download “Lyyti Event” and sign up with the same email address you normally use for event registrations. The app only displays events associated with the email address used to create your account. \n\n\n\nIf you register for events using multiple email addresses\, your registrations will be split across separate app accounts. For the best experience\, please use one consistent email address for all Lyyti registrations. We hope this new functionality makes it easier for you to manage your participation. \n\n\n\n\nYou may also be interested in:\n\n\n\n\nThe PROMISE Initiative: Accelerating Cancer Innovation
URL:https://www.scilifelab.se/event/scilifelab-science-summit-2/
LOCATION:Uppsala Konsert & Kongress (UKK)\, Vaksala torg 1\, Uppsala\, 753 31\, Sweden
CATEGORIES:Event
ATTACH;FMTTYPE=image/jpeg:https://www.scilifelab.se/wp-content/uploads/2025/12/Web-banner.jpg
ORGANIZER;CN="SciLifeLab Event":MAILTO:events@scilifelab.se
END:VEVENT
END:VCALENDAR